Copyright
©The Author(s) 2025.
World J Clin Cases. Oct 16, 2025; 13(29): 110948
Published online Oct 16, 2025. doi: 10.12998/wjcc.v13.i29.110948
Published online Oct 16, 2025. doi: 10.12998/wjcc.v13.i29.110948
Table 2 Evidencebased intervention modalities for postpartum depression
Modality | Core elements | Key evidence (illustrative) | Target population | Evidence grade |
Drug | Brexanolone 60 hours IV; zuranolone 14 days oral; conventional SSRIs | Brexanolone phaseIII (n = 246): Mean ΔPHQ19 = -17.0 (95%CI: -19.3 to -14.7) within brexanolone arm, -14.5 vs placebo; zuranolone phaseII: Rapid onset | Moderatetosevere PPD; lactating mothers with careful evaluation | IA |
Psychological/psychotherapy | CBT (facetoface/online); IPT (partner/group); MBCT | CBT metaanalysis 2022 (31 RCTs) SMD -0.62; coupleIPT RCT ΔEPDS -4.1; MBCTPD trial: 50% relapserisk reduction | Mildtomoderate PPD or women declining drugs | IA |
Exercise/lifestyle | ≥ 150 minutes per week moderate aerobic exercise; highfiber diet; vitaminD supplementation | Systematic review 2022 (35 studies) RR 0.77; highfiber diet improves gut microbiota & mood | Women ≥ 6 weeks postpartum who are physically able | IB |
Integrated/community | CHW “Thinking Healthy” module; digital appbased CBT; WHO mhGAP + group IPT | WHO mhGAP + nurseled groupIPT RCT in Nepal: ΔEPDS -4.3 | Resourcelimited or lowaccess settings | II |
Neuromodulation (pilot/protocol) | Anodal prefrontal tDCS 2 mA × 20 minutes, 10 sessions | Protocol only: Sun et al[52], 2023 RCT design; planned n = 120, primary outcome ΔEPDS at 4 weeks | Moderate PPD unresponsive to CBT/SSRI | NR |
- Citation: Ji QQ, Wang MY. Epidemiology, pathophysiology, and interventions for postpartum depression: Systematic review. World J Clin Cases 2025; 13(29): 110948
- URL: https://www.wjgnet.com/2307-8960/full/v13/i29/110948.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v13.i29.110948